- Home
- BIVI vs IBIO Comparison
BIVI vs IBIO Comparison
Compare BIVI & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- IBIO
- Stock Information
- Founded
- BIVI 2013
- IBIO 2008
- Country
- BIVI United States
- IBIO United States
- Employees
- BIVI N/A
- IBIO N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- IBIO Health Care
- Exchange
- BIVI Nasdaq
- IBIO Nasdaq
- Market Cap
- BIVI 11.9M
- IBIO 11.9M
- IPO Year
- BIVI N/A
- IBIO N/A
- Fundamental
- Price
- BIVI $1.87
- IBIO $0.93
- Analyst Decision
- BIVI
- IBIO Strong Buy
- Analyst Count
- BIVI 0
- IBIO 2
- Target Price
- BIVI N/A
- IBIO $5.50
- AVG Volume (30 Days)
- BIVI 316.9K
- IBIO 2.1M
- Earning Date
- BIVI 11-12-2025
- IBIO 11-11-2025
- Dividend Yield
- BIVI N/A
- IBIO N/A
- EPS Growth
- BIVI N/A
- IBIO N/A
- EPS
- BIVI N/A
- IBIO N/A
- Revenue
- BIVI N/A
- IBIO $400,000.00
- Revenue This Year
- BIVI N/A
- IBIO N/A
- Revenue Next Year
- BIVI N/A
- IBIO N/A
- P/E Ratio
- BIVI N/A
- IBIO N/A
- Revenue Growth
- BIVI N/A
- IBIO 77.78
- 52 Week Low
- BIVI $1.42
- IBIO $0.56
- 52 Week High
- BIVI $75.00
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- BIVI 33.55
- IBIO 64.71
- Support Level
- BIVI $1.54
- IBIO $0.77
- Resistance Level
- BIVI $1.68
- IBIO $0.97
- Average True Range (ATR)
- BIVI 0.14
- IBIO 0.07
- MACD
- BIVI 0.26
- IBIO 0.01
- Stochastic Oscillator
- BIVI 73.77
- IBIO 82.62
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.